SRRK
HealthcareScholar Rock Holding Corporation · Biotechnology · $6B
What is Scholar Rock Holding Corporation?
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on developing medicines that target protein growth factor signaling pathways. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company is advancing treatments for serious diseases with limited options.
Scholar Rock discovers and develops therapies that modulate how protein growth factors are activated in the body. Its lead program, Apitegromab, targets myostatin activation and has completed Phase 3 trials for spinal muscular atrophy. A second candidate, SRK-181, is in Phase 1 trials for cancers resistant to checkpoint inhibitor therapies. The company also collaborates with Gilead Sciences to develop inhibitors targeting fibrotic diseases, broadening its pipeline beyond neuromuscular disorders.
Scholar Rock was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Apitegromab — Phase 3 myostatin inhibitor for spinal muscular atrophy
- SRK-181 — Phase 1 candidate for checkpoint-inhibitor-resistant cancers
- Gilead Sciences collaboration targeting fibrotic disease pathways
- Pipeline programs in neuromuscular disorders, cancer, and fibrosis
Is SRRK a Good Stock to Buy?
UQS Score rates SRRK as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue biotechs.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet and near-term financial exposure are managed better than many peers at a similar development stage. This provides some runway as clinical programs advance.
Quality, Moat, and Growth all register as Weak, which is consistent with a company that has not yet commercialized a product. Valuation is rated Elevated, meaning the current market price may already reflect optimistic clinical outcomes.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SRRK pay dividends?
No — Scholar Rock Holding Corporation does not currently pay a dividend.
Scholar Rock does not pay a dividend. As a clinical-stage biopharmaceutical company, it directs available capital toward research, clinical trials, and pipeline development rather than shareholder distributions. This is standard practice for pre-revenue biotechs where reinvestment in drug development is the primary use of funds.
When does SRRK report earnings?
Scholar Rock reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than revenue or profitability metrics. Pipeline milestones and partnership updates tend to drive market attention around each reporting period.
For the most recent quarter's results and management commentary, visit Scholar Rock's investor relations page directly.
SRRK Price History
+79.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Scholar Rock Holding Corporation?
Based on Scholar Rock Holding Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SRRK Long-term Outlook
Scholar Rock's fundamental outlook is shaped by binary clinical risk. With Growth and Quality both rated Weak, the near-term trajectory depends heavily on regulatory and clinical outcomes for Apitegromab rather than organic business momentum. The Valuation pillar is rated Elevated, which suggests the market has priced in a degree of success — leaving limited margin of safety if trial results disappoint. The Good Risk rating offers some reassurance that the company is not in immediate financial distress.
Growth drivers
- Potential regulatory approval and commercialization of Apitegromab for spinal muscular atrophy
- Expansion of the Gilead Sciences fibrosis collaboration into new indications
- Advancement of SRK-181 through oncology clinical development
Key risks
- Clinical trial failure or regulatory rejection for lead pipeline candidates
- Elevated valuation leaves little buffer if development timelines slip
- Ongoing cash consumption with no commercial revenue yet established
SRRK vs Peers
Scholar Rock operates in a competitive clinical-stage and specialty biotech landscape alongside companies pursuing distinct therapeutic strategies.
Alkermes is a commercial-stage company with approved products in addiction and CNS disorders, giving it a revenue base that Scholar Rock has not yet established.
TG Therapeutics focuses on B-cell malignancies and autoimmune diseases, with a commercialized product portfolio that differentiates it from Scholar Rock's pre-revenue pipeline.
Erasca targets RAS/MAPK pathway-driven cancers, making it a clinical-stage oncology peer with a different mechanistic focus than Scholar Rock's growth factor inhibition approach.
Frequently Asked Questions
What does Scholar Rock do?
Scholar Rock is a clinical-stage biopharmaceutical company that develops medicines targeting protein growth factor signaling. Its lead drug, Apitegromab, is designed to treat spinal muscular atrophy by inhibiting myostatin activation. The company also has an oncology program and a fibrosis collaboration with Gilead Sciences.
Does SRRK pay dividends?
No, Scholar Rock does not pay a dividend. The company is pre-revenue and allocates its capital toward clinical development and research operations. Dividend payments are not typical for companies at this stage of drug development.
When does SRRK report earnings?
Scholar Rock reports on a quarterly cadence, as required for US-listed public companies. Because it has no commercial revenue, reports center on cash position and pipeline updates. Check the company's investor relations page for the current reporting schedule.
Is SRRK a good stock to buy?
UQS Score rates SRRK as Poor overall, driven by Weak readings across Quality, Moat, and Growth — all consistent with a pre-revenue biotech. The Risk pillar is rated Good, but Valuation is Elevated. Whether the risk-reward suits your portfolio depends on your tolerance for binary clinical outcomes. View the full pillar breakdown on UQS Pro.
Is SRRK overvalued?
The UQS Valuation pillar for SRRK is rated Elevated, suggesting the current price may already reflect optimistic assumptions about clinical success. For a company without commercial revenue, valuation is largely driven by pipeline probability estimates rather than traditional earnings-based metrics.
How does SRRK compare to its competitors?
Compared to peers like Alkermes and TG Therapeutics — both of which have approved, revenue-generating products — Scholar Rock is at an earlier commercial stage. Erasca is a closer clinical-stage analog in oncology, though it targets a different biological pathway. The UQS competitor comparison module provides a side-by-side quality view.
What is SRRK's market cap bracket?
Scholar Rock is classified as a mid-cap company. This places it above micro- and small-cap biotechs in terms of market size, though it remains significantly smaller than large-cap pharmaceutical peers with established commercial franchises.
Who founded Scholar Rock?
Scholar Rock was founded in 2012. Founding details and leadership history are publicly available through the company's official website and SEC filings, which provide the most accurate and current information.
Is SRRK a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates SRRK as Poor. The Weak Moat and Quality pillar ratings reflect the absence of a commercial product and durable competitive advantages. Long-term quality could improve materially if Apitegromab reaches the market and generates sustainable revenue. Pro members can track pillar changes over time.
What is the main competitive advantage of Scholar Rock?
Scholar Rock's differentiation lies in its proprietary platform for selectively targeting the activation of latent growth factors — a mechanism that is distinct from most existing biologics. Its collaboration with Gilead Sciences also provides validation and resources that smaller clinical-stage peers typically lack.
What sector does SRRK belong to?
SRRK operates in the Healthcare sector, specifically within the biopharmaceutical and clinical-stage drug development segment. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to benchmark Scholar Rock against sector peers.
Is SRRK a growth stock or value stock?
Based on UQS pillar ratings, SRRK does not fit neatly into either category. The Growth pillar is rated Weak — reflecting no commercial revenue — while Valuation is rated Elevated, which is inconsistent with a traditional value profile. It is best characterized as a high-risk clinical-stage biotech bet.
Unlock Full SRRK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for SRRK
- ✓Access detailed financial metrics and trend data
- ✓Compare SRRK side-by-side with biotech peers
- ✓Track pillar changes as clinical milestones develop
- ✓Screen for higher-quality healthcare stocks by pillar
- ✓Get the complete analyst-grade quality view in one place
Pro Analysis
SRRK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 12.1 | 0.0 | 10.0 | 0.0 | 63.8 | 0.0 | -0.6 |
| Apr 2, 2026 | 12.7 | 0.0 | 10.0 | 0.0 | 67.9 | 0.0 | — |
SRRK — Pillar Breakdown
Quality
— 0.0/100 (25%)Scholar Rock Holding Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Scholar Rock Holding Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 63.8/100 (15%)Scholar Rock Holding Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Scholar Rock Holding Corporation appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 10/100 (25%)Scholar Rock Holding Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SRRK.
Score Composition
Financial Data
More Stock Analysis
How is the SRRK UQS Score Calculated?
The UQS (Unified Quality Score) for Scholar Rock Holding Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Scholar Rock Holding Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Scholar Rock Holding Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.